Merck & Co., Inc. Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of $335.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2014-02-27
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2013-12-31 was $87.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2013-09-30 was -$165.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2013-06-30 was $64.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2013-03-31 was $349.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2013 was $335.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2012 was -$198.00M.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2011 was -$143.00M, a 219.17% decline from fiscal 2010.
- Merck & Co., Inc. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2010 was $120.00M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|---|---|---|
| 2013-12-31 | $87.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$78.00M derived: sum of 2 quarters · filed 2014-02-27 | -$14.00M derived: sum of 3 quarters · filed 2014-02-27 | $335.00M 10-K · filed 2014-02-27 |
| 2013-09-30 | -$165.00M 10-Q · filed 2013-11-07 | -$101.00M derived: sum of 2 quarters · filed 2013-11-07 | $248.00M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $64.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $413.00M 10-Q · filed 2013-08-07 | ||
| 2013-03-31 | $349.00M 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | -$198.00M 10-K · filed 2014-02-27 | |||
| 2011-12-31 | -$143.00M 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $120.00M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | -$316.00M 10-K · filed 2012-02-28 | |||
| 2008-12-31 | $291.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |